BAG-1 and Breast Cancer Outcomes
Author Information
Author(s): Millar E K A, Anderson L R, McNeil C M, O'Toole S A, Pinese M, Crea P, Morey A L, Biankin A V, Henshall S M, Musgrove E A, Sutherland R L, Butt A J
Primary Institution: Garvan Institute of Medical Research
Hypothesis
BAG-1 expression predicts patient outcomes and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast.
Conclusion
High BAG-1 expression is associated with improved patient outcomes in ER-positive breast cancer and may enhance responsiveness to tamoxifen.
Supporting Evidence
- High BAG-1 mRNA expression is associated with improved survival.
- High nuclear BAG-1 expression predicts better outcomes for local recurrence and distant metastases.
- BAG-1 overexpression enhances tamoxifen-induced growth arrest in MCF-7 cells.
Takeaway
BAG-1 is a protein that helps doctors understand how well a breast cancer patient might respond to treatment. If a patient has a lot of BAG-1, they are more likely to do well with tamoxifen, a common breast cancer medicine.
Methodology
BAG-1 expression was assessed using immunohistochemistry in 292 patients, and gene expression data was analyzed to determine relationships with patient outcomes.
Potential Biases
Potential biases may arise from the single-surgeon treatment and the retrospective analysis of patient data.
Limitations
The study may have limitations due to the retrospective nature and potential biases in patient selection and treatment.
Participant Demographics
The study included 292 patients diagnosed with invasive ductal carcinoma, with a focus on ER-positive cases.
Statistical Information
P-Value
P=0.009
Confidence Interval
95% CI: 0.114–0.735
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website